Clinical characteristics and outcomes of Chronic Hepatitis C (CHC) patients treated with newer Direct-Acting Antiviral (DAA)-based regimens from a large us payer perspective
Abstract
Authors
N. Tandon J. Forlenza A. Goolsby Hunter S.D. Korrer A. Buikema